• Je něco špatně v tomto záznamu ?

BDNF, sHLA-G, and sTREM-1 are useful blood biomarkers for identifying grade IV glioma patients

K. Kluckova, J. Kozak, M. Svajdler, J. Steno, V. Matejcik, V. Durmanova, E. Zsemlye, M. Bucova

. 2023 ; 70 (1) : 166-176. [pub] 20230127

Jazyk angličtina Země Slovensko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004294

Inflammation and immunity belong to the main factors influencing tumor growth. In this study, we attempted to identify a profile of biomarkers associated with gliomas. We found decreased serum levels of sTREM-1 (soluble triggering receptor expressed on myelocytes) and increased levels of IL-10 in all grades of glioma patients in comparison with healthy controls (sTREM-1: grade II: p=0.0051, grade III: p=0.02, grade IV: p=0.01; IL-10: grade II: p=0.0017, grade III: p=0.03, grade IV: p=0.007). However, we did not find any combination of tested markers with good sensitivity and specificity in grades II and III of glioma patients to discriminate them from healthy controls. In grade IV glioma patients, two sets of markers showed promising results in distinguishing patients from healthy people. For the first set consisting of four selected markers, sTREM-1, sHLA-G, BDNF, and IL-13, the ROC curves indicate a good discriminatory capability for glioblastoma patients (AUC=0.9510). The best discriminatory capability for glioblastoma patients (AUC=0.9534) was found for the second set consisting of three selected markers sTREM-1, sHLA-G, and BDNF with 79.2% sensitivity and 94.1% specificity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004294
003      
CZ-PrNML
005      
20230425141252.0
007      
ta
008      
230418s2023 xo f 000 0|eng||
009      
AR
024    7_
$a 10.4149/neo_2023_221129N1147 $2 doi
035    __
$a (PubMed)36704922
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Kluckova, Kristina $u Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
245    10
$a BDNF, sHLA-G, and sTREM-1 are useful blood biomarkers for identifying grade IV glioma patients / $c K. Kluckova, J. Kozak, M. Svajdler, J. Steno, V. Matejcik, V. Durmanova, E. Zsemlye, M. Bucova
520    9_
$a Inflammation and immunity belong to the main factors influencing tumor growth. In this study, we attempted to identify a profile of biomarkers associated with gliomas. We found decreased serum levels of sTREM-1 (soluble triggering receptor expressed on myelocytes) and increased levels of IL-10 in all grades of glioma patients in comparison with healthy controls (sTREM-1: grade II: p=0.0051, grade III: p=0.02, grade IV: p=0.01; IL-10: grade II: p=0.0017, grade III: p=0.03, grade IV: p=0.007). However, we did not find any combination of tested markers with good sensitivity and specificity in grades II and III of glioma patients to discriminate them from healthy controls. In grade IV glioma patients, two sets of markers showed promising results in distinguishing patients from healthy people. For the first set consisting of four selected markers, sTREM-1, sHLA-G, BDNF, and IL-13, the ROC curves indicate a good discriminatory capability for glioblastoma patients (AUC=0.9510). The best discriminatory capability for glioblastoma patients (AUC=0.9534) was found for the second set consisting of three selected markers sTREM-1, sHLA-G, and BDNF with 79.2% sensitivity and 94.1% specificity.
650    _2
$a lidé $7 D006801
650    _2
$a receptor TREM-1 $7 D000073871
650    _2
$a mozkový neurotrofický faktor $7 D019208
650    _2
$a interleukin-10 $7 D016753
650    12
$a glioblastom $7 D005909
650    _2
$a biologické markery $7 D015415
650    12
$a gliom $7 D005910
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kozak, Jan $u Department of Neurosurgery, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
700    1_
$a Svajdler, Marian $u Cytopathos, Ltd., Bratislava, Slovakia $u Sikl's Department of Pathology, Charles University, The Faculty of Medicine and Faculty Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Steno, Juraj $u Department of Neurosurgery, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
700    1_
$a Matejcik, Viktor $u Department of Neurosurgery, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
700    1_
$a Durmanova, Vladimira $u Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Zsemlye, Eszter $u Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
700    1_
$a Bucova, Maria $u Institute of Immunology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
773    0_
$w MED00003470 $t Neoplasma $x 0028-2685 $g Roč. 70, č. 1 (2023), s. 166-176
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36704922 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141249 $b ABA008
999    __
$a ok $b bmc $g 1924770 $s 1190503
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 70 $c 1 $d 166-176 $e 20230127 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace